- Home
- MSGS vs PODD Comparison
MSGS vs PODD Comparison
Compare MSGS & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSGS | PODD |
|---|---|---|
| Founded | 1879 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.2B |
| IPO Year | 2015 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MSGS | PODD |
|---|---|---|
| Price | $400.09 | $141.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 21 |
| Target Price | $341.29 | ★ $341.48 |
| AVG Volume (30 Days) | 235.4K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.41 | N/A |
| EPS | 0.32 | ★ 2.67 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | N/A | $24.55 |
| Revenue Next Year | $4.52 | $19.18 |
| P/E Ratio | $1,233.25 | ★ $53.01 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $207.90 | $126.40 |
| 52 Week High | $438.93 | $354.88 |
Technical Indicators
Market Signals| Indicator | MSGS | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 45.59 |
| Support Level | $379.27 | $139.67 |
| Resistance Level | $408.67 | $153.33 |
| Average True Range (ATR) | 8.24 | 4.99 |
| MACD | 0.63 | 0.23 |
| Stochastic Oscillator | 85.14 | 48.27 |
Price Performance
Historical ComparisonAbout MSGS Madison Square Garden Sports Corp. (New)
Madison Square Garden Sports Corp is owns and operates a portfolio of assets featuring some of the recognized teams in all of sports, including the Knicks of the National Basketball Association (NBA) and the Rangers of the National Hockey League (NHL). The company has one operating and reportable segment.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.